Shanghai Institute of Medicine, Chinese Academy of Medical Sciences and Jiangxi National Pharmaceutical Company

Jiangxi National Pharmaceutical is a prominent Chinese pharmaceutical company that serves as a key commercialization and manufacturing partner for the Chinese Academy of Medical Sciences (CAMS). The company is notably the manufacturer of Icaritin (Alite), a first-in-class small molecule derived from traditional Chinese medicine approved in 2022 for the treatment of advanced hepatocellular carcinoma. Jiangxi National Pharmaceutical also produces established blockbuster therapies for cardiovascular and cerebrovascular conditions, including Dengzhan Shengmai Capsules and the fibrinolytic enzyme Defibrase (Ahylysantinfarct). Based in Nanchang, Jiangxi, the company maintains strategic R&D partnerships with CAMS research institutes, including the Shanghai Institute of Medicine, to modernize traditional therapies and develop innovative chemical drugs. The company bridges the gap between academic research and large-scale industrial production, specializing in oncology, neurology, and cardiovascular health.